Volitionrx Ltd (VNRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Volitionrx Ltd (VNRX) has a cash flow conversion efficiency ratio of 0.154x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.49 Million) by net assets ($-35.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Volitionrx Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Volitionrx Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read VNRX liabilities breakdown for a breakdown of total debt and financial obligations.
Volitionrx Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Volitionrx Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LL Lucky Games publ AB
ST:LADYLU
|
-0.071x |
|
LiqTech International Inc
NASDAQ:LIQT
|
-0.205x |
|
TEAM PLC
F:1WQ
|
N/A |
|
Epsium Enterprise Limited Ordinary Shares
NASDAQ:EPSM
|
N/A |
|
Nexen Tire Prf 1
KO:002355
|
0.034x |
|
Lammhults Design Group AB (publ)
ST:LAMM-B
|
-0.029x |
|
Dev Information Technology Limited
NSE:DEVIT
|
0.054x |
|
Eureka Design Public Company Limited
BK:UREKA
|
0.002x |
Annual Cash Flow Conversion Efficiency for Volitionrx Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Volitionrx Ltd from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Volitionrx Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-35.59 Million | $-19.68 Million | 0.553x | -44.24% |
| 2024-12-31 | $-26.11 Million | $-25.89 Million | 0.992x | -52.16% |
| 2023-12-31 | $-8.71 Million | $-18.06 Million | 2.073x | -57.56% |
| 2022-12-31 | $-3.13 Million | $-15.28 Million | 4.886x | +515.21% |
| 2021-12-31 | $17.72 Million | $-20.85 Million | -1.177x | -16.45% |
| 2020-12-31 | $16.29 Million | $-16.46 Million | -1.010x | -12.62% |
| 2019-12-31 | $14.20 Million | $-12.74 Million | -0.897x | +26.07% |
| 2018-12-31 | $12.14 Million | $-14.73 Million | -1.214x | +0.89% |
| 2017-12-31 | $9.96 Million | $-12.19 Million | -1.224x | -186.32% |
| 2016-12-31 | $21.18 Million | $-9.06 Million | -0.428x | +70.51% |
| 2015-12-31 | $6.04 Million | $-8.77 Million | -1.450x | +87.10% |
| 2014-12-31 | $368.18K | $-4.14 Million | -11.247x | -148.21% |
| 2013-12-31 | $680.67K | $-3.08 Million | -4.531x | -63.23% |
| 2012-12-31 | $833.79K | $-2.31 Million | -2.776x | -79.29% |
| 2011-12-31 | $1.09 Million | $-1.69 Million | -1.548x | -3905.47% |
| 2010-12-31 | $-114.29K | $-4.65K | 0.041x | -23.90% |
| 2009-12-31 | $-107.54K | $-5.75K | 0.053x | +112.84% |
| 2008-12-31 | $-95.92K | $39.95K | -0.416x | -288.41% |
| 2007-12-31 | $-78.32K | $-17.31K | 0.221x | -75.14% |
| 2006-12-31 | $-56.23K | $-50.00K | 0.889x | +185417.27% |
| 2005-12-31 | $-72.94K | $35.00 | 0.000x | -148.77% |
| 2004-12-31 | $-64.03K | $-63.00 | 0.001x | -- |
About Volitionrx Ltd
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleos… Read more